Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
2646 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-04-10 (thepharma.media)
Organon acquires the rights to Actemra biosymyr in the United States
Bio-Thera Solutions, the developer of bioanalog, will continue to own the rights to produce a product.
Read more
2025-04-02 (pharmaceutical-technology.com)
Organon acquires Actemra biosimilar's US rights from Biogen
Organon has announced the acquisition from Biogen of US regulatory and commercial rights for intravenous infusion of Tofidence.
Read more
2025-04-01 (marketbeat.com)
Headlands Technologies LLC Acquires 27,129 Shares of Biogen Inc. (NASDAQ:BIIB)
Headlands Technologies LLC lifted its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 2,173.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 28,377 shares of the biotechnology company's stock after acquiring an additional 27,129 shares dur
Read more
2025-04-01 (managedhealthcareexecutive.com)
Organon Expands Biosimilar Portfolio With Tofidence Acquisition
Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the U.S. market, launching in May 2024.
Read more
2025-04-01 (investing.com)
Organon acquires US rights to arthritis biosimilar TOFIDENCE By
Organon acquires US rights to arthritis biosimilar TOFIDENCE
Read more
2025-03-24 (marketbeat.com)
Hillsdale Investment Management Inc. Acquires New Holdings in Biogen Inc. (NASDAQ:BIIB)
Hillsdale Investment Management Inc. acquired a new stake in Biogen Inc. (NASDAQ:BIIB - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,610 shares of the biotechnology company's stock, valued at approximat
Read more
2025-02-13 (endpts.com)
Biogen downplays capacity for M&A; Roche's SMA drug is approved as a tablet
Biotech news roundup: Odyssey layoffs, GSK relocates vaccine R&D, Aligos raises $105M, Terrain Bio launches, Gates Foundation backs antibiotics research, Neuphoria gets Merck milestone
Read more
2025-02-13 (deraktionaer.de)
The deepest stood since 2013! Biogen share rushes into the basement - the shareholder
Disappointing numbers have been pressing the biogen's biogenic stock for more than one decade. Above all, the multiple sclerosis business and the proceeds with the medication of Skyclary's, which the company incorporated through the takeover of Reata, remained behind the expectations of the market. There is also a weak view.
Read more
2025-02-09 (marketbeat.com)
Entropy Technologies LP Acquires New Holdings in Biogen Inc. (NASDAQ:BIIB)
Entropy Technologies LP bought a new stake in Biogen Inc. (NASDAQ:BIIB - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 34,397 shares of the biotechnology company's stock, valued at approximately $5,260,000.
Read more